Relapsed AML 2009

Author: Prof. Dr. med. Dirk Reinhardt, 05.08.2009, erstellt am: 2009/12/01, Last modification: 2015/06/11

Title International Registry Relapsed AML 2009, Registry of children and adolescents with relapsed or refractory acute myeloid leukeamia (AML), AML-BFM Study Group
Disease Relapsed or refractory acute myeloid leukeamia (AML)
Type International Registry for children and adolescents with relapsed or refractory AML
Problem / Objectives

The international therapy trial Relapsed AML 2001/01 (Int. Inverstigator Prof. Dr. G. J. Kaspers, Amsterdam / Prof. Dr. U. Creutzig, Münster) with the the randomised comparison of L-DNR-FLAG versus FLAG could show, although the preliminary
analysis of the randomised comparison of L-DNR-FLAG versus FLAG showed no significant advantage of the overall survival, that improved remission and less toxicity supported a benefit of L-DNR/FLAG.

As the Relapsed AML 2001/01 was finished in 3/2009, there is still a need to register all children and adolescents with refractory or relapsed AML. This should allow evaluating the incidence, to identify new diagnostic procedures and prognostics factors, improve diagnostic security by central reference diagnostics, and assure qualified expert advice concerning prognosis, therapy, response and
complications. In addition, central material banking will supply selected research projects with patients’ material and enable correlating biological results with clinical data.

Therapy / Study arms

This registry aims to evaluate the incidence and frequency of AML relapses in children and adolescents. Further, a central reference diagnostics for the participating hospitals is offered. The coordination center of the registry will provide clinical advice concerning diagnostics, treatment, prognosis and alternative therapies. To assure an informed advisory service, the administered therapy, treatment response and side effects should be documented. Based on the previous studies and the preliminary results from the international Relapsed AML 2001/01 trial, the registry committee recommended a treatment schedule.

Inclusion Criteria
  • All children and adolescents with relapsed or refractory AML younger than 18 years at diagnosis
Exclusion Criteria
  • Missing informed consense
  • Age > 18years at diagnosis
Recruitment ca. 100 patients / year
Status Start 18.06.2009. The registy will be closed, as soon as a phase-III- trial for theese group of patients will be opened.
Principal Investigator Prof. Dirk Reinhardt


Prof. Dr. med. Dirk Reinhardt
Universitätsklinikum Essen (AöR)
Klinik für Kinderheilkunde III
Hufelandstraße 55
45147 Essen
Telefon +49 (201) 723 3784
Fax +49 (201) 723 5386

Prof. Dr. med. U. Creutzig


Jans-Enno Müller
Universitätsklinikum Essen
Päd. Hämatologie/Onkologie (AML-BFM Studie)
Virchowstr. 171
45122 Essen
Telefon +49 (201) 723-1053
Fax +49 (201) 723-5808


Dr. rer. hort. Martin Zimmermann
Medizinische Hochschule Hannover
Kinderklinik IV, Päd. Onkologie
Carl-Neuberg-Straße 1
30625 Hannover
Telefon +49 (511) 532 3764
Fax +49 (511) 532 90 29

Weitere Informationen San­der A, Zim­mer­mann M, Dworz­ak M, Fleisch­hack G, von Neu­hoff C, Rein­hardt D, Kas­pers GJ, Creut­zig U: Con­se­quent and in­ten­si­fied re­l­ap­se the­ra­py im­pro­ved sur­vi­val in pe­d­ia­tric AML: re­sults of re­l­ap­se tre­at­ment in 379 pa­ti­ents of th­ree conse­cu­ti­ve AML-BFM tri­als. Leu­ke­mia 2010
Link(s) Registration
Literature on AML
Einsendebogen Knochenmarkdiagnostik